Drug Profile


Alternative Names: Aromasin; FCE 24304; Nikidess; PNU 155971

Latest Information Update: 04 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer Emory University; Pfizer
  • Class Androstadienes; Antineoplastics; Small molecules
  • Mechanism of Action Aromatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 23 May 2015 Exemestane is still in phase III trials for Breast cancer (Prevention) in the USA, Canada and Puerto Rico
  • 23 May 2015 No recent reports of development identified - Phase-II for Breast cancer (Neoadjuvant therapy) in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top